Plavix, Prasugrel and Drug Eluting Stents Pilot Trial

Inclusion Criteria: * Subject presenting for clinically indicated PCI with implantation of at least one drug-eluting stent. * No planned use of Glycoprotein IIb/IIIa inhibitors during PCI procedure. * Subject must be taking aspirin or enteric coated aspirin 81 mg-325 mg daily. * Willing to participate and sign an informed consent. Exclusion Criteria: * Subject older than 75 years of age. * Subject weight is 60 kg or less. * Subject who have received intravenous eptifibatide or tirofiban within 48 hours prior to PCI or abciximab within 14 days before or during PCI. * Subject taking warfarin or with clinical indication to resume warfarin post PCI for any indication. * Subject currently requiring daily treatment with NSAID or COX2 inhibitors. * Subject with a known platelet disorder. * Subject with known active pathological bleeding or heightened risk of bleeding including but not limited to: gastrointestinal bleeding within 6 months, recent surgery or trauma. * Subject with a history of a stroke or TIA * Subject with pre-PCI hematocrit or platelet count outside the ranges validated for Verify Now P2Y12 test (33-52% and 119.000-502.000/μL, respectively). * Subject with a history of hepatic impairment * Subject with known NYHA Class III or greater for heart failure. * Inability of subject to provide informed consent. * Subject with known hypersensitivity or contraindication to clopidogrel, prasugrel or ASA, which would result in inability of patient to adhere to trial protocol. * Presence of valvular heart disease left main coronary artery stenosis or urgent need for CABG.